Multivariate Cox proportional hazards model
| . | Failure-free survival . | ||
|---|---|---|---|
| Variable . | HR . | 95% CI . | P value . |
| Pretreatment plasma EBV(+) | |||
| >60 copies/100 µL vs ≤60 copies/100 µL | 2.0 | 1.2-3.5 | .01 |
| IPS | |||
| 3-7 vs 0-2 | 1.7 | 1.0-2.7 | .04 |
| Treatment | |||
| Stanford V vs ABVD | 1.1 | 0.7-1.8 | .63 |
| Histology | .92* | ||
| Mixed cellularity vs other | 1.1 | 0.5-2.6 | .83 |
| Nodular sclerosis vs other | 1.1 | 0.6-2.2 | .68 |
| . | Failure-free survival . | ||
|---|---|---|---|
| Variable . | HR . | 95% CI . | P value . |
| Pretreatment plasma EBV(+) | |||
| >60 copies/100 µL vs ≤60 copies/100 µL | 2.0 | 1.2-3.5 | .01 |
| IPS | |||
| 3-7 vs 0-2 | 1.7 | 1.0-2.7 | .04 |
| Treatment | |||
| Stanford V vs ABVD | 1.1 | 0.7-1.8 | .63 |
| Histology | .92* | ||
| Mixed cellularity vs other | 1.1 | 0.5-2.6 | .83 |
| Nodular sclerosis vs other | 1.1 | 0.6-2.2 | .68 |
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; CI, confidence interval; HR, hazard ratio.
*P value from type III test.